文献速递乳腺癌

地舒单抗辅助治疗绝经后激素受体阳性乳腺癌(ABCSG-18):随机双盲安慰剂对照3期试验的无病生存结果

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-02-19

ABCSG-18研究在奥地利和瑞典58个中心纳入3425例接受芳香化酶抑制剂辅助治疗的绝经后激素受体阳性早期乳腺癌患者,随机接受地舒单抗60mg每6个月皮下注射或安慰剂。中位随访73个月,地舒单抗组无病生存显著改善(HR 0.82,95%CI 0.69-0.98,P=0.0260)。

要点

  • 地舒单抗组无病生存事件240例(14.0%),安慰剂组287例(16.8%)。
  • 地舒单抗组5年无病生存89.2%,8年80.6%;安慰剂组5年87.3%,8年77.5%。
  • 未记录独立裁定的颌骨坏死或确认的非典型股骨骨折病例。

核心结论

  • 地舒单抗是接受芳香化酶抑制剂治疗的绝经后激素受体阳性早期乳腺癌患者的有效且安全的辅助治疗。

研究设计与样本

  • 前瞻性、双盲、安慰剂对照3期试验,在奥地利和瑞典58个中心入组绝经后早期激素受体阳性非转移性乳腺腺癌患者。
  • 患者已完成初始辅助治疗(手术、放疗或化疗或其组合)并正在接受辅助芳香化酶抑制剂治疗。
  • 采用置换区组随机化(区组大小2和4,按既往芳香化酶抑制剂使用、基线腰椎总骨密度评分和中心类型分层),按1:1分配接受地舒单抗60mg皮下注射或匹配安慰剂每6个月一次。
  • 2006年12月18日至2013年7月22日共入组3425例 eligible 患者,地舒单抗组1711例,安慰剂组1709例,另有5例撤回知情同意。
  • 主要终点为随机化后至首次临床骨折时间(既往已报告);本次报告次要终点为意向治疗人群的无病生存(定义为随机化至首次局部或远处转移、对侧乳腺癌、第二原发癌或任何原因死亡证据)。

主要发现

  • 中位随访73个月(IQR 58-95),地舒单抗组240例(14.0%)发生无病生存事件,安慰剂组287例(16.8%)。
  • 地舒单抗组较安慰剂组无病生存显著改善(HR 0.82,95%CI 0.69-0.98,Cox P=0.0260;描述性分析,未控制多重性)。
  • 地舒单抗组5年无病生存89.2%(95%CI 87.6-90.8),8年80.6%(78.1-83.1);安慰剂组5年87.3%(85.7-89.0),8年77.5%(74.8-80.2)。
  • 未记录独立裁定的颌骨坏死或确认的非典型股骨骨折病例。
  • 不良事件总数地舒单抗组1367例(包括521例严重不良事件),安慰剂组1339例(515例严重不良事件)。

关键数值与推荐

  • 无病生存定义:随机化至首次局部或远处转移、对侧乳腺癌、第二原发癌或任何原因死亡证据。
  • 地舒单抗给药方案:60mg皮下注射每6个月一次,芳香化酶抑制剂治疗期间。

临床怎么用

  • 原文结论认为地舒单抗是接受芳香化酶抑制剂治疗的绝经后激素受体阳性早期乳腺癌患者的有效且安全的辅助治疗。

局限性

  • 无病生存分析为描述性分析,未控制多重性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In postmenopausal women with hormone receptor-positive, early-stage breast cancer, treatment with adjuvant aromatase inhibitors is the standard of care, but it increases risk for osteoporosis and fractures. Results from the ABCSG-18 trial showed that use of denosumab as an adjuvant to aromatase inhibitor therapy significantly reduced clinical fractures. Disease-free survival outcomes from ABCSG-18 have not yet been reported. METHODS: Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast, who had completed their initial adjuvant treatment pathway (surgery, radiotherapy, or chemotherapy, or a combination) and were receiving adjuvant aromatase inhibitors, were enrolled at 58 trial centres in Austria and Sweden into this prospective, double-blind, placebo-controlled, phase 3 trial. With permuted block randomisation (block sizes 2 and 4, stratified by previous aromatase inhibitor use, total lumbar spine bone mineral density score at baseline, and type of centre), patients were assigned (1:1) to receive subcutaneous denosumab (60 mg) or matching placebo every 6 months during aromatase inhibitor therapy. The primary endpoint (previously reported) was the time to first clinical fracture after randomisation. The secondary endpoint reported here is disease-free survival (defined as time from randomisation to first evidence of local or distant metastasis, contralateral breast cancer, secondary carcinoma, or death from any cause) in the intention-to-treat population. This study is registered with EudraCT (number 2005-005275-15) and ClinicalTrials.gov (number NCT00556374), and is ongoing for long-term follow-up. FINDINGS: Between Dec 18, 2006, and July 22, 2013, 3425 eligible patients were enrolled and randomly assigned; 1711 to the denosumab group and 1709 to the placebo group (with five others withdrawing consent). After a median follow-up of 73 months (IQR 58-95), 240 (14·0%) patients in the denosumab and 287 (16·8%) in the placebo group had disease-free survival events. Disease-free survival was significantly improved in the denosumab group versus the placebo group (hazard ratio 0·82, 95% CI 0·69-0·98, Cox p=0·0260; descriptive analysis, without controlling for multiplicity). In the denosumab group, disease-free survival was 89·2% (95% CI 87·6-90·8) at 5 years and 80·6% (78·1-83·1) at 8 years of follow-up, compared with 87·3% (85·7-89·0) at 5 years and 77·5% (74·8-80·2) and 8 years in the placebo group. No independently adjudicated cases of osteonecrosis of the jaw or confirmed atypical femoral fractures were recorded. The total number of adverse events was similar in the denosumab group (1367 [including 521 serious] adverse events) and the placebo group (1339 [515 serious]). The most common serious adverse events were osteoarthritis (62 [3·6%] of 1709 in the denosumab group vs 58 [3·4%] of 1690 in the placebo group), meniscus injury (23 [1·3%] vs 24 [1·4%]), and cataract (16 [0·9%] vs 28 [1·7%]). One (<0·1%) treatment-related death (due to pneumonia, septic kidney failure, and cardiac decompensation) occurred in the denosumab group. INTERPRETATION: Denosumab constitutes an effective and safe adjuvant treatment for patients with postmenopausal hormone receptor-positive early breast cancer receiving aromatase inhibitor therapy. FUNDING: Amgen.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019. PMID: 30795951. doi:10.1016/S1470-2045(18)30862-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。